Press Release
Akebia Therapeutics Appoints Ronald C. Renaud Jr. to its Board of Directors
"As a prominent and well-respected industry veteran and visionary, Ron
brings significant experience and tremendous value to the company," said
"I am delighted to join Akebia's Board, particularly at this exciting time for the company. Akebia continues to build momentum as it approaches the Phase 2b data readout for AKB-6548 later this year and prepares to embark on a Phase 3 development program in 2015," said Mr. Renaud. "The potential opportunities for a once-daily, oral treatment option that could safely and effectively treat patients with chronic kidney disease impacted by anemia are significant. A new approach to address this serious medical condition would represent not only a paradigm shift, but a true scientific and medical advancement."
AKB-6548 is currently in Phase 2b development for the treatment of anemia related to chronic kidney disease in patients who are not dependent on dialysis, with results expected in the fourth quarter of 2014.
About
Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements include those about Akebia's strategy, future
plans and prospects, including statements regarding the potential
indications and benefits of AKB-6548 and Akebia's pre-clinical
compounds, the expected timing of the announcement of data from the
Phase 2b study and the commencement of the Phase 3 study, and the
progress of Akebia's early stage research program. The words
"anticipate," "appear," "believe," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "target," "potential," "will,"
"would," "could," "should," "continue," and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement, including the risk that existing preclinical
and clinical data may not be predictive of the results of ongoing or
later clinical trials; the ability of Akebia to successfully complete
the clinical development of AKB-6548 or any other product candidate; the
funding required to develop Akebia's product candidates and operate the
Company, and the actual expenses associated therewith; the content of
decisions made by the FDA and other regulatory authorities; the actual
time it takes to complete the Phase 2b study and analyze the data; the
success of competitors in developing product candidates for diseases for
which Akebia is currently developing its product candidates; and
Akebia's ability to obtain, maintain and enforce patent and other
intellectual property protection for AKB-6548 or any other product
candidates. Other risks and uncertainties include those identified under
the heading "Risk Factors" in Akebia's Quarterly Report on Form 10-Q for
the quarter ended
Investors:
Senior Director, Investor Relations and Corporate
Communications
njones@akebia.com
or
Media:
liz.falcone@fkhealth.com
Source:
News Provided by Acquire Media
Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142
+1 617.871.2098 phone
+1 617.871.2099 fax